Please assess the completion status of the following clinical trial:

Trial Title: Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Men ≥ 65 years of age~Exclusion Criteria:~* Prostate cancer; history of prostate cancer;~* History of breast cancer; benign prostatic hypertrophy;~* Weight \< 60 kg~* Weight \> 135 kg~* Serum k+ \< 3.6 mEq/L;~* Serum mg2+ \< 1.8 mg/dL;~* Hemoglobin \< 9.0 mg/dL;~* Hematocrit \< 26%;~* Hepatic transaminases \> 3x upper limit of normal;~* Baseline Bazett's-corrected QT interval \> 450 ms~* Heart failure due to reduced ejection fraction (left ventricular ejection fraction \< 40%)~* Family or personal history of long-QT syndrome, arrhythmias or sudden cardiac death;~* Concomitant use of any QT interval-prolonging drug.

- Gender: MALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Testosterone - progesterone - placebo (Type: EXPERIMENTAL): Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days
- Testosterone - placebo - progesterone (Type: EXPERIMENTAL): Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo ( 2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
- Progesterone - testosterone - placebo (Type: EXPERIMENTAL): Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days
- Progesterone - placebo - testosterone (Type: EXPERIMENTAL): Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
- Placebo - testosterone - progesterone (Type: EXPERIMENTAL): Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
- Placebo - progesterone - testosterone (Type: EXPERIMENTAL): Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).